Cancer vaccine DCVex NY-ESO-1 (Immune Design)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCancer vaccine DCVex NY-ESO-1 (Immune Design)
Drug Alias NameDCVex/NY-ESO-1 cancer vaccineNY-ESO-1 Cancer vaccine (Immune Design)LV-305IDLV-305
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmune Design
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesImmune DesignMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell Lung

Other Information

ATC CodeN/A
Related LinksN/A